Quest Diagnostics (DGX) Declares Quarterly Dividend, Is The Stock Fully Priced?
Quest Diagnostics (DGX) recently declared a quarterly cash dividend of $0.86 per share, giving income focused investors a fresh data point on the stock's shareholder return profile.
Quest Diagnostics now trades at US$258.44, with a 30 day share price return of 11.89% and a year to date share price gain of 48.71% that has outpaced the recent 0.47% daily pullback and 4.61% 7 day advance.
Scan how Quest Diagnostics’ dividend profile compares with other cash generating healthcare stocks by reviewing the hand picked list of solid balance sheet and fundamentals (24 results) in the same space.
Bulls point to Quest Diagnostics’ strong dividend and recent share price surge. Bears warn the run up already prices in the good news. The numbers now need to show whether that optimism looks expensive or not.
Most Popular Narrative: 2% Overvalued
Quest Diagnostics closed at $258.44, while the analyst consensus Narrative on Simply Wall St pegs fair value near $253.73. This implies a small premium that depends on how its testing and automation story develops over time.
The growing role of Quest Diagnostics as a lab engine for consumer wellness and digital health partners, including new offerings through the Apple Health app, WHOOP Advanced Labs, Humanity Biological Age analysis, and the AD-Detect Alzheimer’s portfolio that is being expanded with an FDA-cleared pTau217 assay in late 2026, is creating additional channels for advanced diagnostics revenue and supports longer term earnings power.
See why 21 investors see Quest Diagnostics as 2% overvalued.
Result: Fair Value of $253.73 (OVERVALUED)
Still, reimbursement cuts under the Protecting Access to Medicare Act and policy shifts affecting ACA and Medicaid volumes could pressure Quest Diagnostics’ pricing power and test demand.
Find out about the key risks to this Quest Diagnostics narrative.
Another View on Quest Diagnostics’ Value
On simple earnings multiples, Quest Diagnostics looks more forgiving than the earlier fair value label suggests. The stock trades on a P/E of 25.3x, which is slightly below peers at 26.1x and the same as the wider US Healthcare group, while the fair ratio sits higher at 27.2x. For investors, that gap points to limited multiple compression risk and a modest valuation cushion if sentiment cools. This raises a clear question: Is the bigger swing now in the fundamentals or in how much investors are willing to pay for each dollar of earnings?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With bulls and bears both making their case around Quest Diagnostics, the most useful move now is to interrogate the numbers yourself and decide how convincing each side looks, given our breakdown of 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Quest Diagnostics?
If you stop with Quest Diagnostics, you risk missing other opportunities that fit your goals just as well, or sometimes even better.
- Target long term compounding potential by reviewing a curated 35 high quality undervalued stocks that pairs quality fundamentals with prices that still look restrained.
- Strengthen your income stream by scanning a focused 5 dividend fortresses built around companies prioritising consistent shareholder payouts.
- Sleep easier at night by filtering for a 30 resilient stocks with low risk scores that emphasises resilient balance sheets and muted volatility.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com